Sponsor: Grayken Center for Addiction TTA, a program of Boston Medical Center Family members (i.e., nuclear family, extended family, chosen family) of people with substance use disorder can positively impact addiction treatment initiation, engagement, retention, as well as sustained recovery. This training will reframe the role of family members in the lives of people with substance use disorder, highlighting the importance of family and social support in achieving optimal health outcomes. The experience of family members… Read more »
Zeroing in on Xylazine
Sponsor: Boston Medical Center Grayken Center for Addiction TTA, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS) Description This training will provide knowledge regarding xylazine, a CNS depressant, which has been linked to an increasing number of overdose deaths in the US. This training will discuss the physiologic effects of xylazine, manifestations of xylazine intoxication, overdose, communicable infections associated with xylazine use, and wound care for persons injecting xylazine. Intended audience Intended audience: Providers,… Read more »
Xylazine and HIV in the Era of Synthetic Street Drugs
Sponsor: National Alliance for HIV Education and Workforce Development This session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This presentation will review the history of US street drug markets since the early 1990s to explain the emergence of xylazine, fentanyl, and crystal methamphetamine… Read more »
Initiation of Buprenorphine in Outpatient Settings
Sponsor: Boston Medical Center Grayken Center for Addiction TA, Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS) This training will cover evidence-based strategies for initiating buprenorphine treatment within ambulatory care practices. Special attention will be directed towards effective measures that support the transition of patients using illicitly manufactured fentanyl onto prescribed buprenorphine. NOTE: This training is 60 minutes long. There will be an optional 30-minute Q&A session following the training, which will not count… Read more »
New Substances of Abuse
Sponsor: NH Alcohol & Drug Abuse Counselors Association This training is designed for clinicians at any skill level to explore and understand the changing nature of chemicals of addiction. New substances of abuse are being created, changed, marketed and promoted to us every day. We are inundated with new kinds of drugs, both prescription and illicit and new combinations that are making headlines. Fentanyl is causing a surge in overdoses and fatalities and newer and… Read more »
Effective Group Treatment: Leveraging CBT and MI in Telehealth Groups
Sponsor: NH Alcohol & Drug Abuse Counselors Association Telehealth is proving to be sustainable and effective as treatment centers have transitioned traditional counseling services to online programs. Counselors are tasked to translate face to face skills to telehealth with limited training to recreate foundational helping. This presentation will provide counselors with the tools to create virtual counseling groups which can be applicable to various levels of care. Participants will obtain skills to enhance group cohesion… Read more »
Neurobiology of Addiction
Sponsor: NH Alcohol & Drug Abuse Counselors Association PRESENTATION:This training is designed to advance our understanding of the biological components of addiction. It addresses both chemical addictions and behavior addictions such as gambling and social media. It is appropriate for clinicians, preventions specialists and administrative staff. The most up to date research and information available will help us to not only understand addiction but inform our plans for recovery, and educate our clients. New chemicals… Read more »
The Evolution of Buprenorphine: Prescribing Practices and Efforts to Increase MOUD Access
Sponsor: The American Osteopathic Academy of Addiction Medicine This talk will describe the distribution of buprenorphine patient caseloads for clinicians prescribing formulations of buprenorphine indicated to treat opioid use disorder, how those caseloads evolve over time, and factors associated higher-volume buprenorphine prescribers. The presentation will also discuss implications for expanding access to medication treatment for opioid use disorder and state and federal policy efforts. At the conclusion of trhe seminar learners will be able to:… Read more »
Update on the U.S. Overdose Crisis: Which Drugs, Who is Dying, and How do we Save Lives?
Sponsor: The American Osteopathic Academy of Addiction Medicine In this talk, the presenter will review findings from national and local epidemiological studies on recent changes in U.S. overdose mortality. In recent years, overdose deaths increasingly involve polysubstance, namely opioids and stimulants. Fentanyl dominates almost everywhere, but the other specific drugs implicated vary regionally. Overdose rates are quickly rising among populations that previously had relatively low overdose mortality, including older adults, teens, Black people, and Hispanic/Latine… Read more »
Brixadi (buprenorphine-XR) for the Treatment of Opioid Use Disorder
Sponsor: The American osteopathic Academy of Addiction Medicine During this lecture participants will learn how to treat patients with opioid use disorder using the newly FDA-approved injectable formulation of buprenorphine, Brixadi. At the conclusion of this seminar, participants will be able to: For more information and to register click here